Compare CSGP & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSGP | ILMN |
|---|---|---|
| Founded | 1987 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.1B | 19.4B |
| IPO Year | 1998 | 2000 |
| Metric | CSGP | ILMN |
|---|---|---|
| Price | $38.90 | $131.40 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 17 |
| Target Price | $69.14 | ★ $124.24 |
| AVG Volume (30 Days) | ★ 5.6M | 1.2M |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 170.87 |
| EPS | 0.02 | ★ 5.45 |
| Revenue | $965,230,000.00 | ★ $4,343,000,000.00 |
| Revenue This Year | $19.71 | $6.47 |
| Revenue Next Year | $12.40 | $5.58 |
| P/E Ratio | $1,997.00 | ★ $24.43 |
| Revenue Growth | ★ 15.23 | N/A |
| 52 Week Low | $34.75 | $73.86 |
| 52 Week High | $97.43 | $155.53 |
| Indicator | CSGP | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 40.84 | 56.39 |
| Support Level | $34.75 | $127.99 |
| Resistance Level | $49.03 | $136.86 |
| Average True Range (ATR) | 1.75 | 5.00 |
| MACD | 0.45 | 0.89 |
| Stochastic Oscillator | 63.38 | 67.23 |
CoStar Group is a leading provider of commercial real estate data and marketplace listing platforms. Its data offering contains in-depth analytical information on over 5 million commercial real estate properties related to various subsectors spanning office, retail, hotels, multifamily, healthcare, industrial, self-storage, and data centers. It operates many well-respected brands such as CoStar Suite, LoopNet, Apartments.com, BizBuySell, and Lands of America, with more than 80% of its revenue classified as subscription-based. The company recently expanded its presence into Canada, the United Kingdom, Spain, and France.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.